Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
Intellia’s lonvo-z cut HAE attacks 87% in Phase 3 and started a rolling FDA filing. The clinical case is strong; the commercial ceiling is the debate.
Solar Foods raised €77.8 million from Business Finland for Factory 02, planned to lift Solein output from 160 to 12,800 tonnes a year. The funding is conditional on a final investment decision and full financing. Two gas-fermentation peers have collapsed. What actually decides the bet.
Epoch Biodesign raised $12M (total $50M+) to scale enzyme-based nylon 6,6 recycling. Its AI-designed cascade recovers 90%+ of monomers from blended textiles at ambient temperature. A demo facility near Imperial College London targets 20,000 t/yr by 2028, with INVISTA as MoU partner.
Moderna's mRNA-1010 flu vaccine beat a standard-dose shot by 26.6% relative efficacy, cleared a 9-0 advisory vote, and faces an FDA decision on August 5. What approval would mean for the flu vaccine business.
J&J paid $785M for an exclusive $2.58B option on Sail Biomedicines' in vivo CAR-T platform — a cell therapy that has never reached a patient. Immune reset without the factory could rewrite immunology economics.
Science Corporation's PRIMA BCI retinal implant received CE mark approval, restoring functional central vision in patients with geographic atrophy due to age-related macular degeneration. First commercial implant expected in Germany September 2026.
FDA AdCom voted 9-3 against Capricor deramiocel for Duchenne cardiomyopathy. PDUFA August 22. Lancet published positive HOPE-3 data same day.
A guide to the five-layer tools stack that institutional biotech investors use to gain an edge: pipeline intelligence, financial data, deal tracking, real-world evidence, and signal detection.
Get daily updates on the technologies and investment opportunities shaping the next decade — from AI infrastructure and autonomous systems to biotech, space, and defence. Curated analysis, no noise.
